| Literature DB >> 26556239 |
Hyun Hwan Sung1, Hwang Gyun Jeon1, Deok Hyun Han1, Byong Chang Jeong1, Seong Il Seo1, Hyun Moo Lee1, Han-Yong Choi1, Seong Soo Jeon1.
Abstract
Diagnostic ureterorenoscopy is powerful tool to confirm upper tract urothelial cancer (UTUC). However, URS and associated manipulation may be related to the risk of intravesical recurrence (IVR) following radical nephroureterectomy (RNU). We aimed to investigate whether preoperative ureterorenoscopy would increase IVR after RNU in patients with UTUC. We performed a retrospective analysis of 630 patients who had RNU with bladder cuff excision due to UTUC. Diagnostic URS was performed in 282 patients (44.7%). Patients were divided into two groups according to the URS. Survival analysis and multivariate Cox regression model were performed to address risk factors for the IVR. The interval from URS to RNU was measured. During URS, manipulation such as biopsy and resection was determined. The median age was 64 (IQR 56-72) years with follow-up duration of 34.3 (15.7-64.9) months. Median time from URS to RNU was 16 (0-38) days. The IVR developed in 42.5% (n = 268) patients at 8.2 (4.9-14.7) months. The five-year IVR-free survival rate was 42.6 ± 8.0% and 63.6 ± 6.9% in patients with and without preoperative URS, respectively (P < 0.001). In multivariate analysis, previous history of bladder tumour, extravesical excision of distal ureter, multifocal tumour, and URS (HR, 95% CI; 1.558, 1.204-2.016, P = 0.001) were independent predictors for higher IVR. The IVR rate in patients without manipulation during URS was not different to those with manipulation (P = 0.658). The duration from URS to RNU was not associated with IVR (P = 0.799). Diagnostic URS for UTUC increased IVR rate after RNU. However, the lessening of interval from URS to radical surgery or URS without any manipulation could not reduce the IVR rate.Entities:
Mesh:
Year: 2015 PMID: 26556239 PMCID: PMC4640521 DOI: 10.1371/journal.pone.0139976
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Baseline characteristics of all patients, and clinicopathologic features according to preoperative ureterorenoscopy.
| All patients ( | PreOP URS (-) ( | PreOP URS (+) ( |
| |
|---|---|---|---|---|
| Sex, male, % (n) | 73.8 (465) | 72.7 (253) | 75.2 (212) | 0.482 |
| Age, yr, median (IQR) | 64 (56–72) | 65 (55–71) | 64 (57–72) | 0.752 |
| FU duration, months, median (IQR) | 34.3 (15.7–64.9) | 39.3 (16.1–80.1) | 30.1 (15.2–54.1) | <0.001 |
| Case number (quintile), % (n) | <0.001 | |||
| 1~126 | 84.9 (107) | 15.1 (19) | ||
| 127~252 | 72.2 (91) | 27.8 (35) | ||
| 253~378 | 43.7 (55) | 56.3 (71) | ||
| 379~504 | 37.3 (47) | 62.7 (79) | ||
| 505~630 | 38.1 (48) | 61.9 (78) | ||
| Laterality, Rt, % (n) | 46.3 (292) | 45.1 (157) | 47.9 (135) | 0.490 |
| ASA score, II or greater, % (n) | 68.6 (432) | 67.5 (235) | 69.9 (197) | 0.531 |
| Ureter involved, % (n) | 50.2 (316) | 49.1 (171) | 51.4 (145) | 0.569 |
| Multifocal tumor, % (n) | 26.7 (168) | 25.0 (87) | 28.7 (81) | 0.293 |
| Previous bladder tumor, % (n) | 19.5 (123) | 22.7 (79) | 15.6 (44) | 0.025 |
| Surgical approach, % (n) | <0.001 | |||
| Open | 62.2 (392) | 72.4 (252) | 49.6 (140) | |
| Laparoscopic | 37.8 (238) | 27.6 (96) | 50.4 (142) | |
| Bladder cuffing, transvesical, % (n) | 57.3 (361) | 63.8 (222) | 49.3 (139) | <0.001 |
| Tumor grade, III, % (n) | 44.9 (277) | 44.5 (153) | 45.4 (124) | 0.815 |
| Tumor stage | <0.001 | |||
| Ta | 17.3 (109) | 14.4 (50) | 20.9 (59) | |
| T1 | 24.3 (153) | 19.8 (69) | 29.8 (84) | |
| T2 | 16.3 (103) | 15.8 (55) | 17.0 (48) | |
| T3 and T4 | 42.1 (265) | 50.0 (174) | 32.3 (91) | |
| LN status, positive, % (n) | 8.9 (56) | 10.3 (36) | 7.1 (20) | 0.154 |
| CIS, positive, % (n) | 10.5 (66) | 8.6 (30) | 12.8 (36) | 0.094 |
| Tumor size, cm, median (IQR) | 3.5 (2.3–5.0) | 4.0 (3.0–5.5) | 3.0 (1.8–4.0) | <0.001 |
| Margin, positive, % (n) | 4.9 (31) | 6.6 (23) | 2.8 (8) | 0.030 |
| LVI, positive, % (n) | 17.1 (108) | 17.8 (62) | 16.3 (46) | 0.618 |
| Adjuvant chemotherapy, % (n) | 20.3(128) | 21.3 (74) | 19.1 (54) | 0.512 |
ASA, American Society of Anesthesiologists; CIS, carcinoma in situ; FU, follow-up; HR, hazard ratio; CI, confidence interval; IQR, interquartile range; LN, lymph node; LVI, lymphovascular invasion; URS, ureterorenoscopy.
Fig 1Survival analysis of intravesical recurrence in all patients (A), and according to previous bladder tumor history (B) following radical nephroureterectomy.
Fig 2Survival analysis of intravesical recurrence according to preoperative ureterorenoscopy in all patients (A, n = 630) and excluding prior bladder tumor history (B, n = 507) following radical nephroureterectomy.
Risk factors for predicting intravesical recurrence following radical nephroureterectomy for upper tract urothelial cancer in 630 patients.
| Univariate Analysis | Multivariate Analysis | |||
|---|---|---|---|---|
| HR (95% CI) |
| HR (95% CI) |
| |
| Sex, female | 0.919 (0.692–1.221) | 0.561 | ||
| Age, continuous | 1.007 (0.995–1.018) | 0.264 | ||
| Case number (quintile) | 0.008 | 0.099 | ||
| 1~126 | Referent | Referent | ||
| 127~252 | 1.432 (0.967–2.121) | 0.073 | 1.152 (0.770–1.723) | 0.490 |
| 253~378 | 2.042 (1.389–3.001) | <0.001 | 1.457 (0.953–2.230) | 0.083 |
| 379~504 | 1.629 (1.081–2.453) | 0.020 | 0.942 (0.591–1.501) | 0.801 |
| 505~630 | 1.586 (1.009–2.494) | 0.046 | 0.936 (0.571–1.534) | 0.793 |
| ASA score, II or greater | 1.216 (0.936–1.581) | 0.143 | 1.067 (0.815–1.396) | 0.718 |
| Ureter involvement | 1.158 (0.911–1.472) | 0.232 | ||
| Multifocal tumor | 1.397 (1.076–1.814) | 0.012 | 1.398 (1.055–1.853) | 0.020 |
| Previous bladder tumor history | 2.369 (1.813–3.095) | <0.001 | 2.535 (1.903–3.376) | <0.001 |
| Surgical approach, laparoscopic | 1.087 (0.847–1.394) | 0.512 | ||
| Cuffing type, extravesical | 1.568 (1.229–1.999) | <0.001 | 1.411 (1.075–1.852) | 0.013 |
| Tumor grade, III | 0.984 (0.770–1.257) | 0.897 | ||
| Tumor stage | 0.881 | |||
| Ta | Referent | |||
| T1 | 1.066 (0.740–1.534) | 0.733 | ||
| T2 | 1.094 (0.737–1.623) | 0.656 | ||
| T3 or 4 | 0.967 (0.691–1.354) | 0.847 | ||
| LN, positive | 0.641 (0.374–1.099) | 0.106 | 0.558 (0.322–0.967) | 0.038 |
| CIS, positive | 1.304 (0.914–1.861) | 0.143 | 0.827 (0.566–1.209) | 0.328 |
| Size, continuous | 1.027 (0.979–1.078) | 0.277 | ||
| Margin, positive | 1.994 (1.232–3.228) | 0.005 | 1.646 (0.992–2.732) | 0.054 |
| LVI, positive | 0.912 (0.647–1.286) | 0.598 | ||
| Adjuvant chemotherapy | 0.860 (0.633–1.166) | 0.331 | ||
| Ureterorenoscopy | 1.550 (1.218–1.972) | <0.001 | 1.558 (1.204–2.016) | 0.001 |
ASA, American Society of Anesthesiologists; CIS, carcinoma in situ; HR, hazard ratio; CI, confidence interval; IQR, interquartile range; LN, lymph node; LVI, lymphovascular invasion; URS, ureterorenoscopy.
Fig 3Survival analysis of intravesical recurrence according to manipulation.
mani, manipulation; URS, ureterorenoscopy; w, with; w/o, without.
Fig 4Survival analysis of intravesical recurrence between concurrent ureterorenoscopy with radical nephroureterectomy group (n = 72) versus preceding ureterorenoscopy and delayed radical nephroureterectomy group (n = 210).